Indian pharmaceutical stocks took a hit as Trump’s threat of imposing tariffs on pharma imports spooked investors. Despite India’s strong presence in the US generics market, potential tariffs may increase costs for US consumers and create supply chain challenges.
Motilal Oswal initiates coverage on Adani Enterprises with Buy, sees 25% upside. Here’s why
Motilal Oswal has initiated coverage on Adani Enterprises with a Buy rating and a target price of Rs 3,880, implying 25% upside from the prevailing